Metabolic Characteristics of Plasma OxPLs in STEMI Patients.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: STEMI - ST-segment Elevation Myocardial Infarction. Basic parameters: 50 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Metabolic Characteristics of Plasma OxPLs in STEMI Patients and Its Value Analysis in Predicting MACEs Risk After PCI Surgery.
Overview
The goal of this observational study is to investigate the structural composition and metabolic characteristics of OxPLs in STEMI patients. Explore OxPLs characteristic fingerprint biomarkers from different populations and analyze OxPLs fingerprint spectra. Based on the OxPLs fingerprint of STEMI patients, a machine learning classifier is used to establish an artificial intelligence assisted post PCI MACE risk prediction system, achieving the transformation of basic research into clinical application.
Primary outcome measures
- Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0 [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- The patient meets the diagnostic criteria for STEMI (refer to the "Diagnosis and Treatment Guidelines for Acute ST Segment Elevation Myocardial Infarction (2021)")
- Agree to perform direct PCI
- The onset time is less than 12 hours and successfully undergoing emergency PCI treatment
- After admission, all STEMI patients are routinely treated with antiplatelet aggregation, anticoagulation, lipid-lowering, and anti myocardial remodeling drugs.
Exclusion criteria
- Previous history of myocardial infarction
- Accompanied by other cardiovascular diseases, such as severe heart valve disease, severe heart failure, congenital heart disease, cardiomyopathy, etc
- Merge with severe infection
- Merge with severe anemia
- Merge with severe liver and kidney dysfunction
- Combined with malignant tumors
- Accompanied by a history of autoimmune or hematological diseases
- Recent history of severe trauma or surgery
- Patients with incomplete clinical data
- The patient does not agree to undergo data collection
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
China · 1 center
- First Affiliated Hospital of Ningbo University — Ningbo
Identifiers
NCT: NCT07382700 · 2025004A